Evidence mapPaperPMID 37139410Full record

ReviewActa pharmaceutica Sinica. B2023

Recent advances in diverse nanosystems for nitric oxide delivery in cancer therapy.

Dan Gao, Sajid Asghar, Rongfeng Hu, Su Chen, Ruixin Niu, Jia Liu, Zhipeng Chen, Yanyu Xiao

Open access · diamondAbstract readReview
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 59 citations in OpenAlex.

  1. NO-PDT and chemotherapy: spatiotemporal control to achieve therapeutic synergy.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2026
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Dan GaoState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Sajid AsgharFaculty of Pharmaceutical Sciences, Government College University Faisalabad, Faisalabad 38000, Pakistan.
Rongfeng HuAnhui Province Key Laboratory of Pharmaceutical Preparation Technology and Application, Hefei 230012, China.
Su ChenState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Ruixin NiuState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
Jia LiuJiangyin Hospital Affiliated to Nanjing University of Chinese Medicine, Jiangyin 214499, China.
Zhipeng ChenDepartment of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Yanyu XiaoState Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China.
China Pharmaceutical University · CNNanjing University of Chinese Medicine · CNGovernment College University, Faisalabad · PK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gas therapy has been proven to be a promising and advantageous treatment option for cancers. Studies have shown that nitric oxide (NO) is one of the smallest structurally significant gas molecules with great potential to suppress cancer. However, there is controversy and concern about its use as it exhibits the opposite physiological effects based on its levels in the tumor. Therefore, the anti-cancer mechanism of NO is the key to cancer treatment, and rationally designed NO delivery systems are crucial to the success of NO biomedical applications. This review summarizes the endogenous production of NO, its physiological mechanisms of action, the application of NO in cancer treatment, and nano-delivery systems for delivering NO donors. Moreover, it briefly reviews challenges in delivering NO from different nanoparticles and the issues associated with its combination treatment strategies. The advantages and challenges of various NO delivery platforms are recapitulated for possible transformation into clinical applications.

Indexed as

Anti-cancerBinding mechanismsInorganic platformsNitric oxideNitric oxide-based delivery systemNitric oxide donorOrganic platformsSynergistic treatment strategy

Identifiers

PMID37139410
PMCPMC10149905
OpenAlexW4309635092

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.